Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform NaV1.7.

Mulcahy JV, Pajouhesh H, Beckley JT, Delwig A, Du Bois J, Hunter JC.

J Med Chem. 2019 Oct 10;62(19):8695-8710. doi: 10.1021/acs.jmedchem.8b01906. Epub 2019 May 7.

PMID:
31012583
2.

A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG.

Sci Transl Med. 2015 Jun 3;7(290):290ra89. doi: 10.1126/scitranslmed.aaa5597.

PMID:
26041706
3.

Modular, efficient synthesis of asymmetrically substituted piperazine scaffolds as potent calcium channel blockers.

Borzenko A, Pajouhesh H, Morrison JL, Tringham E, Snutch TP, Schafer LL.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3257-61. doi: 10.1016/j.bmcl.2013.03.114. Epub 2013 Apr 4.

PMID:
23639535
4.

Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM.

PLoS One. 2013;8(2):e56265. doi: 10.1371/journal.pone.0056265. Epub 2013 Feb 18. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/76780c06-ac81-48a3-8cce-509da6858fe5.

5.

Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.

Pajouhesh H, Feng ZP, Zhang L, Pajouhesh H, Jiang X, Hendricson A, Dong H, Tringham E, Ding Y, Vanderah TW, Porreca F, Belardetti F, Zamponi GW, Mitscher LA, Snutch TP.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):4153-8. doi: 10.1016/j.bmcl.2012.04.054. Epub 2012 Apr 19.

6.

T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures.

Tringham E, Powell KL, Cain SM, Kuplast K, Mezeyova J, Weerapura M, Eduljee C, Jiang X, Smith P, Morrison JL, Jones NC, Braine E, Rind G, Fee-Maki M, Parker D, Pajouhesh H, Parmar M, O'Brien TJ, Snutch TP.

Sci Transl Med. 2012 Feb 15;4(121):121ra19. doi: 10.1126/scitranslmed.3003120.

7.

A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain.

Hildebrand ME, Smith PL, Bladen C, Eduljee C, Xie JY, Chen L, Fee-Maki M, Doering CJ, Mezeyova J, Zhu Y, Belardetti F, Pajouhesh H, Parker D, Arneric SP, Parmar M, Porreca F, Tringham E, Zamponi GW, Snutch TP.

Pain. 2011 Apr;152(4):833-43. doi: 10.1016/j.pain.2010.12.035. Epub 2011 Feb 23.

PMID:
21349638
8.

Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors.

Pajouhesh H, Feng ZP, Ding Y, Zhang L, Pajouhesh H, Morrison JL, Belardetti F, Tringham E, Simonson E, Vanderah TW, Porreca F, Zamponi GW, Mitscher LA, Snutch TP.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83. doi: 10.1016/j.bmcl.2010.01.008. Epub 2010 Jan 7.

PMID:
20117000
9.

Scaffold-based design and synthesis of potent N-type calcium channel blockers.

Zamponi GW, Feng ZP, Zhang L, Pajouhesh H, Ding Y, Belardetti F, Pajouhesh H, Dolphin D, Mitscher LA, Snutch TP.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. doi: 10.1016/j.bmcl.2009.09.008. Epub 2009 Sep 11.

PMID:
19815411
10.

A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers.

Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, Shimizu Y, Janke DL, Parker D, Mezeyova J, Khawaja A, Pajouhesh H, Fraser RA, Arneric SP, Snutch TP.

Assay Drug Dev Technol. 2009 Jun;7(3):266-80. doi: 10.1089/adt.2009.191.

PMID:
19530894
11.

Medicinal chemical properties of successful central nervous system drugs.

Pajouhesh H, Lenz GR.

NeuroRx. 2005 Oct;2(4):541-53. Review.

12.

Pharmacological profile of the isomers of the GluR-specific agonist ATPA.

Curry K, Pajouhesh H.

Can J Physiol Pharmacol. 1998 Jun;76(6):690-2.

PMID:
9923408
13.

Phase transition properties of aqueous dispersions of homologues of all-trans 2,3-dipalmitoylcyclopentano-1-phosphocholine.

Jain MK, Singer MA, Crecely RW, Pajouhesh H, Hancock AJ.

Biochim Biophys Acta. 1984 Jul 25;774(2):199-205.

PMID:
6743654
14.
16.
17.

Potential anticonvulsants VI: condensation of isatins with cyclohexanone and other cyclic ketones.

Pajouhesh H, Parson R, Popp FD.

J Pharm Sci. 1983 Mar;72(3):318-21. No abstract available.

PMID:
6842387
18.

Potential anticonvulsants IV: Condensation of isatin with benzoylacetone and isopropyl methyl ketone.

Popp FD, Pajouhesh H.

J Pharm Sci. 1982 Sep;71(9):1052-4. No abstract available.

PMID:
7131274

Supplemental Content

Loading ...
Support Center